Hydroxysafflor yellow A 羟基红花黄色素A; Safflomin A; HSYA|cas:78281-02-4|西域试剂

Hydroxysafflor yellow A 羟基红花黄色素A; Safflomin A; HSYA,96.27%

产品编号：Bellancom-N0567| CAS NO：78281-02-4| 分子式：C₂₇H₃₂O₁₆| 分子量：612.53

羟基红花黄色素A (Hydroxysafflor yellow A)是从中药红花中分离出的黄酮类天然产物，具有抗癌活性。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-N0567		￥800.00	杭州北京（现货）
Bellancom-N0567		￥2600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Hydroxysafflor yellow A 羟基红花黄色素A; Safflomin A; HSYA

产品介绍

羟基红花黄色素A (Hydroxysafflor yellow A)是从中药红花中分离出的黄酮类天然产物，具有抗癌活性。

生物活性

Hydroxysafflor yellow A is a flavonoid derived and isolated from traditional Chinese medicine Carthamus tinctorius L., possesses anti-tumor activity. IC50 value: Target: in vitro: HYSA could inhibit LPS-induced VSMCs proliferation and migration, accompanied by the downregulated levels of several key pro-inflammatory cytokines, including TNF-α, IL-6, and IL-8. We further showed that HYSA inhibited LPS-induced upregulation of TLR-4 expression as well as the activation of Rac1/Akt pathway . HSYA protected EC viability against LPS-induced injury (P<0.05). LPS-induced NF-κB p65 subunit DNA binding (P<0.01) and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor -α (I-κB-α) phosphorylation was inhibited by HSYA. HSYA attenuated LPS triggered ICAM-1 and E-selectin mRNA levels elevation and phosphorylation of p38 MAPK or c-Jun N-terminal kinase MAPK . HSYA inhibited the proliferation of 3T3-L1 preadipocytes and cell viability greatly decreased in a dose and time dependent manner. HSYA (1 mg/l) notably reduced the amount of intracellular lipid and triglyceride content in adipocytes by 21.3 % (2.13 ± 0.36 vs 2.71 ± 0.40, P < 0.01) and 22.6 % (1.33 ± 0.07 vs 1.72 ± 0.07, P < 0.01) on days 8 following the differentiation, respectively . in vivo: HSYA treatment ameliorated serum biochemical indicators by reducing the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronan (HA), laminin (LN), and type III precollagen (III-C) in rats [4].

体外研究

体内研究

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (408.14 mM; Need ultrasonic)

H₂O : 33.33 mg/mL (54.41 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6326 mL	8.1629 mL	16.3257 mL
5 mM	0.3265 mL	1.6326 mL	3.2651 mL
10 mM	0.1633 mL	0.8163 mL	1.6326 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.40 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.40 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.40 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.40 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献

. Yang G, et al. Hydroxysafflor yellow A inhibits lipopolysaccharide-induced proliferation and migration of vascular smooth muscle cells via Toll-like receptor-4 pathway. Int J Clin Exp Med. 2015 Apr 15;8(4):5295-302. [Content Brief]

. Zhu HJ, et al. Hydroxysafflor yellow A (HYSA) inhibited the proliferation and differentiation of 3T3-L1 preadipocytes. Cytotechnology. 2015 Mar 7. [Content Brief]

. He Y, et al. Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats. J Physiol Biochem. 2015 Mar;71(1):69-78. [Content Brief]

[4]. Jin M, et al. Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury. Chin J Integr Med. 2015 May 27. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

安全声明 (欧洲)	24/25

1. 物质的识别

产品名：	hydroxysafflor-yellow-A
CAS号：	78281-02-4
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	hydroxysafflor-yellow-A
别名：	Safflomin A; HSYA
分子式：	C27H32O16
分子量：	612.53

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	2-8°C, protect from light

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

76. [4.46] Jiaxi Chen et al."Hydroxysafflor yellow A protects against colitis in mice by suppressing pyroptosis via inhibiting HK1/NLRP3/GSDMD and modulating gut microbiota."TOXICOLOGY AND APPLIED PHARMACOLOGY.2023 May;467:116494

75. [5.195] Zelin Lai et al."Hydroxysafflor yellow a confers neuroprotection against acute traumatic brain injury by modulating neuronal autophagy to inhibit NLRP3 inflammasomes."JOURNAL OF ETHNOPHARMACOLOGY.2023 May;308:116268

74. [0] Xiaoqing Song et al."Protective effect of hydroxysafflor yellow A on MSCs against senescence induced by D-galactose."Chinese Herbal Medicines.2022 Dec;:

73. [1.698] Mengjie Xue et al."Illumination on Chemical Compounds from Qufeng Zhitong Capsule and Its Potential Pharmacological Mechanism against Rheumatoid Arthritis Based on UHPLC/Q-Orbitrap-MS Combined with Network Pharmacology Analysis."International Journal of A

72. [6.656] Jiling Feng et al."Luhong Formula and Hydroxysafflor yellow A protect cardiomyocytes by inhibiting autophagy."PHYTOMEDICINE.2023 Feb;110:154636

71. [7.425] Zhen Yan et al."Composition of major quinochalcone hydroxysafflor yellow A and anhydrosafflor yellow B is associated with colour of safflower (Carthamus tinctorius) during colour-transition but not with overall antioxidant capacity: a study on 144 cultiva

70. [IF=2.65] Jing Zhou et al."Buyang Huanwu Decoction: A Traditional Chinese Medicine, Promotes Lactate-Induced Angiogenesis in Experimental Intracerebral Hemorrhage."Evidence-based Complementary and Alternative Medicine.2022 Oct 30;2022:4063315

69. [IF=7.419] Yule Wang et al."Discovery of anti-stroke active substances in Guhong injection based on multi-phenotypic screening of zebrafish."BIOMEDICINE & PHARMACOTHERAPY.2022 Nov;155:113744

68. [IF=2.464] Zhou Huifen et al."Pharmacokinetic-Pharmacodynamic Modeling of Active Components from Salvia miltiorrhiza (Danshen) and Carthamus tinctorius (Honghua) in Focal Cerebral Ischemia Rats."Revista Brasileira de Farmacognosia-Brazilian Journal of Pharmacognosy.

67. [IF=6.53] Qianqian Chen et al."Pharmacokinetic-pharmacodynamic modeling analysis for hydroxysafflor yellow A-calycosin in compatibility in normal and cerebral ischemic rats: A comparative study."Biomed Pharmacother. 2022 Jun;150:112950

66. [IF=3.269] Dan Su et al."Hydroxysafflor yellow A inhibits the proliferation, migration, and invasion of colorectal cancer cells through the PPARγ/PTEN/Akt signaling pathway."Bioengineered. 2021;12(2):11533-11543

65. [IF=6.529] Ting Shang et al."The combination of four main components in Xuebijing injection improved the preventive effects of Cyclosporin A in acute graft-versus-host disease mice by protecting intestinal microenvironment."Biomed Pharmacother. 2022 Apr;148:112675

64. [IF=5.34] Yule Wang et al."Guhong injection promotes post-stroke functional recovery via attenuating cortical inflammation and apoptosis in subacute stage of ischemic stroke."Phytomedicine. 2022 May;99:154034

63. [IF=0.533] Jinyan Jiang et al."Comparative studies of the anti-thrombotic effects of saffron and HongHua based on network pharmacology."Trop J Pharm Res. 2020 Nov;19(7):1441-1448

62. [IF=1.902] Rui Yao et al."Pharmacokinetic characteristics of hydroxysafflor yellow A in normal and diabetic cardiomyopathy mice."Biomed Chromatogr. 2021 Oct;35(10):e5173

61. [IF=1.902] Ting Zhang et al."The influence of essential oils from ZhaLi NuSi Prescription on the pharmacokinetics of its non-volatile components in normal rats."Biomedical Chromatography. 2021 Oct 21

60. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950

59. [IF=3.098] Donglai Zhou et al."Hydroxysafflor Yellow A mitigated myocardial ischemia/reperfusion injury by inhibiting the activation of the JAK2/STAT1 pathway."Int J Mol Med. 2019 Aug;44(2):405-416

58. [IF=4.225] Shang Ting et al."Xuebijing Injection Maintains GRP78 Expression to Prevent Candida albicans–Induced Epithelial Death in the Kidney."Front Pharmacol. 2020 Jan;0:1416

57. [IF=4.36] Li Lin et al."Study on the alleviation of Fengshi Gutong capsule on rheumatoid arthritis through integrating network pharmacology and experimental exploration."J Ethnopharmacol. 2021 Nov;280:114471

56. [IF=4.545] Na Wu et al."Hydroxysafflor yellow A promotes apoptosis via blocking autophagic flux in liver cancer."Biomed Pharmacother. 2021 Apr;136:111227

55. [IF=5.34] Jing Zhang et al."Application of “spider-web” mode in discovery and identification of Q-markers from Xuefu Zhuyu capsule."Phytomedicine. 2020 Oct;77:153273

54. [IF=5.81] Fangma Yijia et al."Hydroxysafflor Yellow A and Anhydrosafflor Yellow B Protect Against Cerebral Ischemia/Reperfusion Injury by Attenuating Oxidative Stress and Apoptosis via the Silent Information Regulator 1 Signaling Pathway."Front Pharmacol. 2021 Sep

53. [IF=7.271] Teng Li et al."Integrated metabolomics and network pharmacology to reveal the mechanisms of hydroxysafflor yellow A against acute traumatic brain injury."Comput Struct Biotec. 2021 Jan;19:1002

52. [IF=7.514] Xin Tong et al."Greener extraction process and enhanced in vivo bioavailability of bioactive components from Carthamus tinctorius L. by natural deep eutectic solvents."Food Chem. 2021 Jun;348:129090

51. [IF=7.514] Liuwei Zhao et al."Safflomin A: A novel chemical marker for Carthamus tinctorius L. (Safflower) monofloral honey."Food Chem. 2022 Jan;366:130584

50. [IF=2.1] Bin Ni et al."Hydroxysafflor yellow A protects against angiotensin II‑induced hypertrophy."Mol Med Rep. 2018 Oct;18(4):3649-3656

49. [IF=2.173] Wenlu Li et al."Hydroxysafflor yellow A protects methylglyoxal-induced injury in the cultured human brain microvascular endothelial cells."Neurosci Lett. 2013 Aug;549:146

48. [IF=2.233] Zhenzhen Ni et al."Inhibitory effects of hydroxysafflor yellow A on the formation of advanced glycation endproducts in vitro."Biological & Pharmaceutical Bulletin. 2012 Aug 31

47. [IF=2.547] Jing Zhou et al."Pharmacokinetic Study on Protocatechuic Aldehyde and Hydroxysafflor Yellow A of Danhong Injection in Rats with Hyperlipidemia."Pharmacology. 2018;102(3-4):154-160

46. [IF=2.896] Lu Wang et al."Rapid assay for testing superoxide anion radical scavenging activities to natural pigments by ultra-high performance liquid chromatography-diode-array detection method."Anal Methods-Uk. 2015 Feb;7(4):1535-1542

45. [IF=3.046] Liwei Dong et al."Echinacoside induces apoptotic cancer cell death by inhibiting the nucleotide pool sanitizing enzyme MTH1."Oncotargets Ther. 2015; 8: 3649–3664

44. [IF=3.845] Zhang Xianhua et al."Danshen-Chuanxiong-Honghua Ameliorates Cerebral Impairment and Improves Spatial Cognitive Deficits after Transient Focal Ischemia and Identification of Active Compounds."Front Pharmacol. 2017 Jul;0:452

43. [IF=5.81] Yu Li et al."Pharmacokinetics of Active Components From Guhong Injection in Normal and Pathological Rat Models of Cerebral Ischemia: A Comparative Study."Front Pharmacol. 2018 May;0:493

42. [IF=10.618] Yao-Xiong Huang et al."Versatile on-stage microfluidic system for long term cell culture, micromanipulation and time lapse assays."Biosens Bioelectron. 2018 Mar;101:66

41. Zhang, Jing, et al. "Application of “spider-web” mode in discovery and identification of Q-markers from Xuefu Zhuyu capsule." Phytomedicine 77 (2020): 153273.https://doi.org/10.1016/j.phymed.2020.153273

40. Jiang, Jinyan, et al. "Comparative studies of the anti-thrombotic effects of saffron and HongHua based on network pharmacology." Tropical Journal of Pharmaceutical Research 19.7 (2020): 1441-1448.https://doi.org/10.4314/tjpr.v19i7.16

39. Yu, Lu, et al. "Hydroxysafflor yellow a confers neuroprotection from focal cerebral ischemia by modulating the crosstalk between JAK2/STAT3 and SOCS3 signaling pathways." Cellular and molecular neurobiology (2020): 1-11.

38. Zhou, Donglai, et al. "Hydroxysafflor Yellow A mitigated myocardial ischemia/reperfusion injury by inhibiting the activation of the JAK2/STAT1 pathway." International journal of molecular medicine 44.2 (2019): 405-416.https://doi.org/10.3892/ijmm.2019.4230

37. Wu, Na, et al. "Hydroxysafflor yellow A promotes apoptosis via blocking autophagic flux in liver cancer." Biomedicine & Pharmacotherapy 136 (2021): 111227.https://doi.org/10.1016/j.biopha.2021.111227

36. 黄楷迪,刘敬霞,牛阳,马学琴,张婷,卜凡淑,任慧,郭盛,钱大玮,段金廒.回药扎里奴思方UPLC指纹图谱结合多成分含量测定的质控方法研究[J].南京中医药大学学报,2021,37(01):77-82.

35. 李燕霞,王琳,姚弘毅.HSYA对骨关节炎大鼠膝关节软骨损伤的修复作用研究[J].局解手术学杂志,2021,30(03):195-199.

34. 谢飞,周美兰.羟基红花黄色素A抑制高糖诱导的小鼠肾足细胞损伤[J].基础医学与临床,2021,41(01):27-32.

33. 支旭然刘洪涛吴茵等. UPLC-MS/MS法同时测定肾康注射液中7个有效成分[J]. 药物分析杂志 2017 037(001):37-42.

32. 李正, 潘万芳, 朱立明,等. 基于物质流分析的丹红注射液制药过程质量控制研究[J]. 天津中医药大学学报, 2015, 34(06):349-352.

31. 支旭然董占军吴茵等. HPLC同时测定肾康注射液中的4种成分[J]. 华西药学杂志 2017(03):297-299.

30. 黄赵刚, 程钢, 汤浩,等. 血必净注射液指纹图谱研究[J]. 中国医院药学杂志, 2018, 038(022):2323-2327.

29. 艾进超何昱杨荣兵等. 丹红注射液中主要有效成分在脑缺血大鼠体内药动学研究[J]. 中草药 2015 46(20):79-84.

28. 刘雪石晓倩吴晏杰等. UPLC法同时测定新安名方脑络欣通中5个活性成分的含量[J]. 贵阳中医学院学报 2020年42卷4期 26-31页 ISTIC 2020.

27. 马梦雪吴士筠李刚等. HPLC法同时测定不同品种红花中4种黄酮类[J]. 中成药 2019 041(011):2694-2700.

26. 方雨晨, 万海同, 虞立,等. 谷红注射液主要有效成分在脑缺血模型大鼠体内的药动学研究[J]. 中国中药杂志, 2018, 043(009):1940-1945.

25. 王亚洲, 杨春旭. 蝎龙酒质量标准研究[J]. 中国实验方剂学杂志, 2012, 18(23):105-108.

24. 王亚洲. 蝎龙接骨散质量标准研究[J]. 黑龙江医药, 2012, 25(6):845-847.

23. 易丽娟, 李雅, 邹苏兰,等. 基于正交试验设计与BP神经网络优化益气活血方水提工艺研究[J]. 中草药, 2019, v.50;No.653(18):50-57.

22. 王亚洲. HPLC法同时测定蝎龙酒中芍药苷羟基红花黄色素A和阿魏酸[J]. 中成药 2012 34(010):1925-1928.

21. 王亚洲杨春旭. HPLC同时测定蝎龙接骨散中羟基红花黄色素A和阿魏酸的含量[J]. 中国实验方剂学杂志 2012 18(22):109-111.

20. 陈俊奎, 万海同, 周惠芬,等. 谷红注射液在脑缺血再灌注大鼠体内药动学与抗氧化作用关联性研究[J]. 中草药, 2016, 47(003):447-453.

19. 施笑晖, 唐映红, 陈建真,等. 谷红注射液中羟基红花黄色素A在大鼠体内的药动学研究[J]. 中成药, 2015, 037(011):2387-2391.

18. 潘璐佳, 万海同, 陈俊奎,等. 谷红注射液中2种成分对脑缺血大鼠氨基酸类神经递质释放的协同作用[J]. 中成药, 2019, 041(004):784-788.

17. 吴鸿,雷震,高水波,张玲霞,代丽萍.羟基红花黄色素A通过抑制微小RNA-1表达对H9c2心肌细胞氧化损伤的保护作用[J].北京中医药大学学报,2018,41(08):636-641.

16. 万甜,吴敏瑞,齐振熙.羟基红花黄色素A对激素诱导骨髓间充质干细胞成骨分化的影响[J].中国骨伤,2014,27(03):224-228.

15. 齐振熙, 吴敏瑞, 万甜,等. 羟基红花黄色素A对激素诱导骨髓间充质干细胞ERK1/2的干预作用[J]. 康复学报, 2014, 24(002):13-16.

14. 侯兆阳, 陈哲, 魏家森. 羟基红花黄色素A对急性脊髓损伤模型大鼠神经细胞凋亡的影响[J]. 浙江中西医结合杂志, 2014, 000(009):753-756.

13. 齐振熙,万甜,吴敏瑞,张占勇,仲卫红,于涛.羟基红花黄色素A不同给药方式对激素性股骨头缺血坏死模兔ERK1/2、JNK和p38蛋白表达的影响[J].中华中医药杂志,2014,29(09):2927-2930.

12. 樊启猛, 刘润南, 贺鹏,等. 经典名方单味药材群体指纹图谱信息熵及一次投料量研究[J]. 时珍国医国药, 2020年31卷4期, 975-979页, PKU CSCD CA, 2020.

11. 万甜,吴敏瑞,齐振熙.红花提取物对激素性股骨头缺血坏死兔股骨头组织ERK、JNK和P38蛋白表达的影响[J].中医杂志,2013,54(23):2039-2042.

10. 杜红芳, 耿魁魁, 李冬梅,等. 注射用红花黄色素与6种输液配伍的稳定性[J]. 中成药, 2014, 036(008):1635-1640.

9. 特日格乐, 韩晓静, 宝乐尔,等. 正交试验优选蒙药红花最佳醇提工艺[J]. 智慧健康, 2020, 006(007):47-48.

8. 李海英, 贺鹏, 樊启猛,等. 桃红四物汤HPLC指纹图谱的总量统计矩及一次稳态投料量分析. 中国实验方剂学杂志.

7. ]贺智勇,邹弢,罗田,李婉蓉,杨佳佳,刘学,肖婷,周雪,吴林菁,刘文,沈祥春,陶玲.基于薄荷油为油相的红花提取物自微乳凝胶递送系统制备研究[J].中草药,2020,51(11):2922-2928.

6. 杜辉马永强李春阳等. 响应面法优化复合酶提取红花黄色素工艺[J]. 南方农业学报 2015 46(004):657-663.

5. 范红晶虞立金伟锋李敏周静李晓红张宇燕.原儿茶醛与羟基红花黄色素A单用与合用在高脂血症大鼠体内的药动学-药效学相关性研究[J].中国中药杂志 2017 42(13):2564-2570.

4. 朱振洪黄小飞王玉周郡潘利峰万海同.丹红注射液与羟基红花黄色素A对大鼠脑缺血再灌注后IL-1β、TNF-α和Caspase-3 mRNA表达的影响[J].中华中医药杂志 2016 31(04):1390-1393.

3. 李宵吴茵支旭然等. UPLC-MS/MS同时测定谷红注射液中7种有效成分[J]. 中国实验方剂学杂志 2017(21):64-69.

2. 徐森玲万海同金湛等. PHPLC法同时分离纯化红花中2种成分[J]. 中成药 2017 39(002):436-439.

1. 陈娟周晔陈伟华等. ICU超剂量谷红注射液成品输液的合理性考察[J]. 临床合理用药杂志 2018 11(31):18-21.